Haemonetics Corporation $HAE Stock Position Lifted by North Peak Capital Management LLC

North Peak Capital Management LLC lifted its position in Haemonetics Corporation (NYSE:HAE) by 204.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,102,992 shares of the medical instruments supplier’s stock after buying an additional 740,626 shares during the period. Haemonetics makes up about 7.5% of North Peak Capital Management LLC’s portfolio, making the stock its 5th largest position. North Peak Capital Management LLC’s holdings in Haemonetics were worth $88,405,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. AQR Capital Management LLC grew its position in shares of Haemonetics by 372.8% in the 3rd quarter. AQR Capital Management LLC now owns 2,128,878 shares of the medical instruments supplier’s stock worth $102,814,000 after buying an additional 1,678,630 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its position in shares of Haemonetics by 994.7% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,380,102 shares of the medical instruments supplier’s stock worth $110,615,000 after buying an additional 1,254,035 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of Haemonetics by 2.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,099,519 shares of the medical instruments supplier’s stock worth $53,587,000 after buying an additional 26,763 shares during the last quarter. Millennium Management LLC grew its position in shares of Haemonetics by 4,296.3% in the 3rd quarter. Millennium Management LLC now owns 773,179 shares of the medical instruments supplier’s stock worth $37,685,000 after buying an additional 755,592 shares during the last quarter. Finally, Fort Washington Investment Advisors Inc. OH grew its position in shares of Haemonetics by 1.5% in the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 716,997 shares of the medical instruments supplier’s stock worth $57,467,000 after buying an additional 10,685 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Stock Performance

Shares of NYSE HAE opened at $77.89 on Friday. The company has a current ratio of 2.95, a quick ratio of 1.87 and a debt-to-equity ratio of 1.53. Haemonetics Corporation has a 12 month low of $47.31 and a 12 month high of $87.32. The company has a 50 day simple moving average of $62.27 and a two-hundred day simple moving average of $67.36. The stock has a market cap of $3.54 billion, a price-to-earnings ratio of 38.56, a PEG ratio of 1.57 and a beta of 0.56.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.29 EPS for the quarter, beating the consensus estimate of $1.28 by $0.01. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. The business had revenue of $346.35 million during the quarter, compared to analysts’ expectations of $336.83 million. During the same period in the previous year, the business posted $1.24 EPS. The business’s quarterly revenue was up 4.8% compared to the same quarter last year. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. As a group, analysts predict that Haemonetics Corporation will post 5.23 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on HAE shares. Robert W. Baird set a $67.00 price objective on shares of Haemonetics in a research report on Friday, May 8th. Citigroup boosted their target price on shares of Haemonetics from $64.00 to $70.00 and gave the stock a “neutral” rating in a research report on Thursday, May 28th. Bank of America raised shares of Haemonetics from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $72.00 to $80.00 in a research report on Friday, May 22nd. JPMorgan Chase & Co. dropped their target price on shares of Haemonetics from $74.00 to $62.00 and set a “neutral” rating on the stock in a research report on Friday, May 8th. Finally, Weiss Ratings downgraded shares of Haemonetics from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, May 21st. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $77.11.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.